MD Anderson Trial Explores Psilocybin-Assisted Therapy for Cancer Mental Health

For oncology nurses, managing the persistent psychological burden of anxiety and depression is a critical frontier in patient care, particularly for those undergoing long-term maintenance therapy.

While advancements in oncology have significantly improved survival rates, The University of Texas MD Anderson Cancer Center is now exploring how to "hijack back" the nervous system using psilocybin-assisted psychotherapy . By utilizing tryptamines to induce neuroplasticity, this pioneering clinical trial aims to offer a holistic therapeutic "package" that enables patients to not only survive their diagnosis but truly thrive.

Led by Dr. Moran Amit, MD Anderson is spearheading a pioneering clinical trial that combines the active ingredient found in so-called "magic mushrooms" with a rigorous psychotherapy framework. This initiative is part of a broader Cancer Neuroscience Program designed to help patients not only survive their diagnosis but truly thrive.

Reprogramming the nervous system

The science behind the trial centers on the relationship between the brain and the disease. "One of the things that we've discovered is that cancer can hijack the nervous system," Amit explained in an interview. The goal of this research is to "hijack it back" by utilizing a class of agents called tryptamines, better known as psychedelics, to induce neuroplasticity and reprogram the nervous system to better support the patient.

Unlike recreational use, this clinical approach is highly controlled. Amit emphasized that the program provides a "package" rather than just a drug. This package integrates the medication with a specific form of talk therapy focused on "acceptance and commitment and leaning towards the storm," a departure from traditional cognitive behavioral therapy.

The importance of "set and setting"

The trial, which began in 2024, is one of the first to study psilocybin specifically for patients with cancer dealing with the side effects of maintenance therapy. To ensure safety and efficacy, the program prioritizes what Amit called the "set and setting."

"The set is basically the mindset," Amit noted. "It’s not just about like, hey, take a pill and go home and have fun. It’s more about to get the patients to a mindset that will be constructive and beneficial for them." This involves multiple preparation sessions where patients set their intentions before the actual dosing day.

The "setting" is equally vital. Dosing occurs in a specialized, "less medicalized" room designed to be receptive and comfortable. During the experience, two trained facilitators remain in the room to monitor the patient and ensure the safest possible experience.

A condensed path to wellness

Following the dosing day, patients participate in integration sessions to process their experience.

According to Amit, the impact can be profound. "The feedback that I’m getting from patients is like, 'You’ve condensed two years of therapy in like 14 days,'" he said.